EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes with MiniMed TM 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 Diabetes

Mary B Abraham iD, Grant J Smith iD, Julie Dart, Elizabeth A Davis iD, Timothy W Jones iD

Diabetes Technology & Therapeutics · 2024-05 · 26 (5) · 341-345

DOI: 10.1089/dia.2023.0508 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 30.04.2024. Verfasst von Mary B Abraham und 4 weiteren Autor:innen. Beteiligte Einrichtung: Children's Diabetes Centre, Telethon Kids Institute, The University of Western Australia, Perth, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Infusion Systems, Blood Glucose, Blood Glucose Self-Monitoring. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced hybrid closed-loop (AHCL) therapy with the Medtronic MiniMed™ 780G system improves glycemia; however, the clinical outcomes in younger children remain less established. This pilot study aimed to explore the continuous glucose monitoring (CGM) metrics in very young children on AHCL. Children between 2 and 7 years of age and on insulin pump therapy were recruited. A 2-week phase in manual mode was followed by a 6-week AHCL phase. CGM metrics were analyzed to review glycemic outcomes. Out of 11 participants enrolled [mean (standard deviation [SD]) age 5.3 (0.8) years], 10 completed the study. Time in closed loop was 96.7 (3.9)%. In AHCL, participants had a mean (SD) time in range of 72.6 (7.4)% and spent 3.0 (1.74)% and 0.63 (0.46)% in time

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin Infusion SystemsBlood GlucoseBlood Glucose Self-MonitoringHypoglycemic AgentsInsulinHumansChildChild, PreschoolMaleFemalePilot ProjectsTreatment OutcomeGlycemic Control

Stichwörter der Autor:innen

CGM metricsHybrid closed-loop therapyType 1 diabetesYoung children

Substanzen

Blood GlucoseHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Children's Diabetes Centre, Telethon Kids Institute, The University of Western Australia, Perth, Australia.
  • Department of Endocrinology and Diabetes, Perth Children's Hospital, Perth, Australia.
  • Centre for Child Health Research, The University of Western Australia, Perth, Australia.
  • Discipline of Paediatrics, Medical School, The University of Western Australia, Perth, Australia.

ORCID-Profile: Mary B Abraham, Grant J Smith, Elizabeth A Davis, Timothy W Jones

Zitieren

APA

Abraham, M. B., Smith, G. J., Dart, J., Davis, E. A., & Jones, T. W. (2024). Clinical Outcomes with MiniMed TM 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 Diabetes. Diabetes Technology & Therapeutics, 26(5), 341-345. https://doi.org/10.1089/dia.2023.0508

Vancouver

Abraham MB, Smith GJ, Dart J, Davis EA, Jones TW. Clinical Outcomes with MiniMed TM 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 Diabetes. Diabetes Technology & Therapeutics. 2024;26(5):341-345. doi:10.1089/dia.2023.0508

BibTeX
@article{Abraham2024,
  author = {Abraham, Mary B and Smith, Grant J and Dart, Julie and Davis, Elizabeth A and Jones, Timothy W},
  title = {Clinical Outcomes with MiniMed TM 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 Diabetes},
  journal = {Diabetes Technology & Therapeutics},
  year = {2024},
  volume = {26},
  number = {5},
  pages = {341--345},
  doi = {10.1089/dia.2023.0508}
}
Kostenlos starten →